Ami Fadia
Analyst, Needham
Replay available
Revolution Medicines, Inc. (RVMD) Q3 2025 Earnings Call
Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2025 earnings conference call, held 2025-11-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Laura Prendergast
Analyst, Stifel
Ryan Asay
Senior Vice President of Corporate Affairs
Dr. Wei Lin
Chief Medical Officer
Charles Zhu
Analyst, LifeSci Capital
Alex Tranahan
Analyst, Bank of America
Jonathan Chang
Analyst, Lyric Partners
Dr. Mark Goldsmith
Chairman and Chief Executive Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Revolution Medicines, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.938 conference call. At this time, all participants are in a listen-only mode. 00:00:04.938 -- 00:00:08.903 After the speaker's presentation, there will be a question and answer session. 00:00:08.903 -- 00:00:13.149 To ask a question during the session, you will need to press star 11 on your telephone. 00:00:13.149 -- 00:00:17.355 You will then hear an automated message advising your hand is raised. 00:00:17.355 -- 00:00:20.359 To withdraw your question, please press star 11 again. 00:00:20.359 -- 00:00:21.761 We 00:00:21.761 -- 00:00:25.587 ask that you please limit to one question and one follow-up. 00:00:25.587 -- 00:00:28.583 Please be advised that today's conference is being recorded. 00:00:28.583 -- 00:00:33.450 I would now like to hand the conference over to your first speaker today, Ryan Asay, 00:00:33.450 -- 00:00:36.034 Senior Vice President of Corporate Affairs. 00:00:36.034 -- 00:00:38.435 Please go ahead. 00:00:39.519 -- 00:00:43.104 Thank you, and welcome to our third quarter 2025 earnings call. 00:00:43.104 -- 00:00:46.990 Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and 00:00:46.990 -- 00:00:52.318 Chief Executive Officer, Dr. Wei Lin, our Chief Medical Officer, and Jack Anders, 00:00:52.318 -- 00:00:57.436 our Chief Financial Officer. Dr. Steve Kelsey, our President of Research and Development, 00:00:57.436 -- 00:01:02.862 Dr. Alan Sandler, our Chief Development Officer, and Anthony Mancini, our Chief 00:01:02.862 -- 00:01:07.808 Global Commercialization Officer, will join us for the Q&A portion of today's call. 00:01:07.808 -- 00:01:11.872 I'd like to inform you that certain statements we make during this call will be forward-looking 00:01:11.872 -- 00:01:16.857 because such statem...